HomeCompareLYPHF vs NNN

LYPHF vs NNN: Dividend Comparison 2026

LYPHF yields 529.73% · NNN yields 5.68%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LYPHF wins by $325.8K in total portfolio value
10 years
LYPHF
LYPHF
● Live price
529.73%
Share price
$0.38
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$351.3K
Annual income
$921.47
Full LYPHF calculator →
NNN
NNN REIT Inc.
● Live price
5.68%
Share price
$41.89
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$2,637.42
Full NNN calculator →

Portfolio growth — LYPHF vs NNN

📍 LYPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLYPHFNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LYPHF + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LYPHF pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LYPHF
Annual income on $10K today (after 15% tax)
$45,027.15/yr
After 10yr DRIP, annual income (after tax)
$783.25/yr
NNN
Annual income on $10K today (after 15% tax)
$482.93/yr
After 10yr DRIP, annual income (after tax)
$2,241.81/yr
At 15% tax rate, NNN beats the other by $1,458.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LYPHF + NNN for your $10,000?

LYPHF: 50%NNN: 50%
100% NNN50/50100% LYPHF
Portfolio after 10yr
$188.4K
Annual income
$1,779.45/yr
Blended yield
0.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

LYPHF
No analyst data
Altman Z
1.5
Piotroski
6/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+7.3% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LYPHF buys
0
NNN buys
0
No recent congressional trades found for LYPHF or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLYPHFNNN
Forward yield529.73%5.68%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%8.6%
Portfolio after 10y$351.3K$25.6K
Annual income after 10y$921.47$2,637.42
Total dividends collected$211.1K$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: LYPHF vs NNN ($10,000, DRIP)

YearLYPHF PortfolioLYPHF Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$37,187$26,486.56$10,737$617.02+$26.4KLYPHF
2$85,815$46,025.42$11,577$710.93+$74.2KLYPHF
3$141,454$49,631.95$12,538$822.59+$128.9KLYPHF
4$189,585$38,229.58$13,645$956.06+$175.9KLYPHF
5$226,799$23,942.82$14,925$1,116.51+$211.9KLYPHF
6$256,060$13,384.38$16,415$1,310.57+$239.6KLYPHF
7$281,045$7,061.29$18,158$1,546.77+$262.9KLYPHF
8$304,340$3,621.64$20,213$1,836.20+$284.1KLYPHF
9$327,476$1,832.63$22,649$2,193.37+$304.8KLYPHF
10$351,321$921.47$25,558$2,637.42+$325.8KLYPHF

LYPHF vs NNN: Complete Analysis 2026

LYPHFStock

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

Full LYPHF Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this LYPHF vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LYPHF vs SCHDLYPHF vs JEPILYPHF vs OLYPHF vs KOLYPHF vs MAINLYPHF vs ADCLYPHF vs EPRTLYPHF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.